HYRISSNCT05633771
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Dec 2026 to Mar 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 8 to 51
- Minor Secondary endpoints: details revised at 1 of 9 entriesv8
- Minor Study sites: 1 to 8v6
- Notable Eligibility criteria expanded, about 37 words
- Study completion date: Dec 15, 2025 to Dec 2026
- Secondary endpoints: details revised at 1 of 9 entries
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Feb 28, 2023 to Feb 16, 2023
- Notable Start date: Dec 15, 2022 to Feb 28, 2023
- Primary and study completion dates: Nov 2, 2026 to Dec 15, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation
Timeframe: Up to 6 months
Secondary (9)
Percentage of patients who discontinue Hyrimoz
Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire
Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire
Percentage of patients with the perception of a high level of disease activity using VAS scale
Percentage of patients with a good perception about biosimilars using VAS scale
Show 4 moreShow less
Percentage of patients in remission
Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]
Ulcerative colitis activity measurement: partial Mayo calculation score
Pattern of Hyrimoz® utilization
Arms and interventions
Hyrimoz
Patients prescribed with Hyrimoz
Other: Hyrimoz
Sites
51 sites in 2 countries
France 38, Belgium 13